Venglustat and Itraconazole DDI Study

Phase 1, open-label, single-arm trial of venglustat in Gaucher disease (GD), Fabry disease (FD) and autosomal dominant polycystic kidney disease (ADPKD), sponsored by Sanofi. Primary endpoints: Area under the plasma concentration versus time curve up to 21 days and Area under the plasma concentration versus time curve calculated from time zero to the real time (tlast) up to 21 days. Started Aug 2018; status: completed.